Sunshine Biopharma (SBFM) Price & Analysis

Q: What was Sunshine Biopharma’s price range in the past 12 months?

Sunshine Biopharma lowest stock price was $1.17 and its highest was $3.90 in the past 12 months.

Q: What is Sunshine Biopharma’s market cap?

Sunshine Biopharma’s market cap is $7.70M.

Q: When is Sunshine Biopharma’s upcoming earnings report date?

Sunshine Biopharma’s upcoming earnings report date is May 13, 2026 which is in 164 days.

Q: How were Sunshine Biopharma’s earnings last quarter?

Sunshine Biopharma released its earnings results on Nov 11, 2025. The company reported -$0.19 earnings per share for the quarter, missing the consensus estimate of -$0.13 by -$0.06.

Q: Is Sunshine Biopharma overvalued?

According to Wall Street analysts Sunshine Biopharma’s price is currently Overvalued. Get more investment ideas with TipRanks Premium

Q: Does Sunshine Biopharma pay dividends?

Sunshine Biopharma does not currently pay dividends.

Q: What is Sunshine Biopharma’s EPS estimate?

Sunshine Biopharma’s EPS estimate for its next earnings report is not yet available.

Q: How many shares outstanding does Sunshine Biopharma have?

Sunshine Biopharma has 4,555,945 shares outstanding.

Q: What happened to Sunshine Biopharma’s price movement after its last earnings report?

Sunshine Biopharma reported an EPS of -$0.19 in its last earnings report, missing expectations of -$0.13. Following the earnings report the stock price went up 1.744%.

Q: Which hedge fund is a major shareholder of Sunshine Biopharma?

Currently, no hedge funds are holding shares in SBFM

Compare

423 Followers

SBFM Stock Chart & Stats

$1.40

-$0.11(-3.50%)

At close: Jan 08 4:00 PM EST

$1.40

-$0.11(-3.50%)

Day’s Range― - ―

52-Week Range$1.17 - $3.90

Previous CloseN/A

Volume70.59K

Average Volume (3M)1.09M

Market Cap

$7.70M

Enterprise Value-$2.89M

Total Cash (Recent Filing)$10.31M

Total Debt (Recent Filing)$929.03K

Price to Earnings (P/E)―

Beta1.59

Next Earnings

May 13, 2026

EPS EstimateN/A

Next Dividend Ex-DateN/A

Dividend YieldN/A

Share Statistics

EPS (TTM)-0.19

Shares Outstanding4,555,945

10 Day Avg. Volume3,175,467

30 Day Avg. Volume1,091,586

Financial Highlights & Ratios

PEG Ratio<0.01

Price to Book (P/B)0.09

Price to Sales (P/S)0.06

P/FCF Ratio-0.14

Enterprise Value/Market Cap-0.38

Enterprise Value/Revenue-0.08

Enterprise Value/Gross Profit-0.24

Enterprise Value/Ebitda0.47

Forecast

1Y Price TargetN/A

Price Target UpsideN/A

Rating ConsensusHold

Number of Analyst Covering0

EPS Forecast (FY)N/A

Revenue Forecast (FY)N/A

Sunshine Biopharma News

SBFM Earnings this Week: How Will it Perform?

Sunshine Biopharma, Inc. (SBFM) is scheduled to report 3rd quarter earnings on 11/11/2025. Regarding Q3 estimates, Wall Street...

21d ago

SBFM

Sunshine Biopharma’s Nora Pharma receives Health Canada approval for domperidone

Sunshine Biopharma’s (SBFM) Nora Pharma has received approval from Health Canada for the commercialization of Domperidone, a prescription...

1M ago

SBFM

Sunshine Biopharma announces commercial launch of doxycycline in Canada

Sunshine Biopharma (SBFM) announced the commercial launch of generic Doxycycline in Canada. This strategic move strengthens the Company’s...

1M ago

SBFM

Sunshine Biopharma’s Nora Pharma launches pravastatin

Sunshine Biopharma’s (SBFM) Nora Pharma has launched Pravastatin, a generic prescription drug in the therapeutic class of Lipid...

2M ago

SBFM

Sunshine Biopharma allocates $5M for investment in bitcoin

Sunshine Biopharma (SBFM) announced its Board of Directors has formally approved a strategic investment of $5M in Bitcoin...

2M ago

SBFM

Sunshine Biopharma, University of Arizona develop series of protease inhibitors

Sunshine Biopharma (SBFM) has developed a new series of orally active, non-covalent protease inhibitors with dose-dependent antiviral activity...

2M ago

SBFM

Sunshine Biopharma’s Nora Pharma launches NIOPEG

Sunshine Biopharma (SBFM) announced that its wholly owned Canadian subsidiary, Nora Pharma, has launched NIOPEG, the company’s first...

5M ago

SBFM

Sunshine Biopharma launches generic gabapentin for neuropathic pain

Sunshine Biopharma (SBFM) announced that its wholly owned Canadian subsidiary, Nora Pharma Inc., has launched Gabapentin, a new...

6M ago

SBFM

Sunshine Biopharma Sees 18% Revenue Growth in Q1 2025

Sunshine Biopharma ( ($SBFM) ) has provided an update. Sunshine Biopharma reported an 18% increase in revenues for...

6M ago

SBFM

Sunshine Biopharma launches generic Lurasidone for schizophrenia

Sunshine Biopharma (SBFM) announced that its wholly owned Canadian subsidiary, Nora Pharma, has launched Lurasidone, a new generic...

7M ago

SBFM

Sunshine Biopharma launches Everolimus in Canada

Sunshine Biopharma (SBFM) announced that its wholly owned Canadian subsidiary, Nora Pharma, has launched Everolimus in the Canadian...

7M ago

SBFM

Is SBFM a Buy, Before Earnings?

Sunshine Biopharma, Inc. (SBFM) is scheduled to report 4th quarter earnings on 04/08/2025. Regarding Q4 estimates, Wall Street...

8M ago

SBFM

Sunshine Biopharma Secures $2.46 Million in Direct Offering

Sunshine Biopharma ( ($SBFM) ) has issued an announcement. Sunshine Biopharma Inc. announced a $2.46 million registered direct...

8M ago

SBFM

Sunshine Biopharma Closes $2.46 Million Direct Offering

An update from Sunshine Biopharma ( ($SBFM) ) is now available. Sunshine Biopharma Inc. announced the successful closing...

8M ago

SBFM

SBFM FAQ

What was Sunshine Biopharma’s price range in the past 12 months?

Sunshine Biopharma lowest stock price was $1.17 and its highest was $3.90 in the past 12 months.

What is Sunshine Biopharma’s market cap?

Sunshine Biopharma’s market cap is $7.70M.

When is Sunshine Biopharma’s upcoming earnings report date?

Sunshine Biopharma’s upcoming earnings report date is May 13, 2026 which is in 164 days.

How were Sunshine Biopharma’s earnings last quarter?

Sunshine Biopharma released its earnings results on Nov 11, 2025. The company reported -$0.19 earnings per share for the quarter, missing the consensus estimate of -$0.13 by -$0.06.

Is Sunshine Biopharma overvalued?

According to Wall Street analysts Sunshine Biopharma’s price is currently Overvalued. Get more investment ideas with TipRanks Premium

Does Sunshine Biopharma pay dividends?

Sunshine Biopharma does not currently pay dividends.

What is Sunshine Biopharma’s EPS estimate?

Sunshine Biopharma’s EPS estimate for its next earnings report is not yet available.

How many shares outstanding does Sunshine Biopharma have?

Sunshine Biopharma has 4,555,945 shares outstanding.

What happened to Sunshine Biopharma’s price movement after its last earnings report?

Sunshine Biopharma reported an EPS of -$0.19 in its last earnings report, missing expectations of -$0.13. Following the earnings report the stock price went up 1.744%.

Which hedge fund is a major shareholder of Sunshine Biopharma?

Currently, no hedge funds are holding shares in SBFM

Company Description

Sunshine Biopharma

Sunshine Biopharma (SBFM) is a biopharmaceutical company focused on the development of innovative therapies for the treatment of cancer and other serious diseases. The company operates in the biotechnology sector, specializing in the research, development, and commercialization of novel drug candidates. SBFM's core products include proprietary compounds targeting various types of cancers, with an emphasis on addressing unmet medical needs through advanced therapeutic solutions.